CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
228
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

- The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors
- CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM
- Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier
- The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments, announced that the first patient in Europe has been enrolled and dosed in France in the company’s ongoing potentially pivotal global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. According to the National Brain Tumor Society, more than 13,000 Americans are expected to receive a GBM diagnosis during 2022, which accounts for 49.1% of all primary malignant brain tumors (https://nnw.fm/HKMgi ).

CNS Pharmaceuticals has opened 29 clinical sites of the 68 sites selected across the United States, Italy, France, Spain, and Switzerland. The company is planning a non-binding futility analysis, which will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at six months which is expected mid-year 2023. The review will include additional evaluation of safety as well as secondary efficacy endpoints, with no pause to enrollment during the interim analysis.

According to CEO John Climaco, the CNS Pharmaceuticals team worked tirelessly to expand its Berubicin clinical trial globally, and the enrolment and dosing of the first patient in France shortly after the opening of the site is a notable accomplishment and confirmation of the team’s commitment to driving the program forward (https://nnw.fm/4hP0b ).

“I am pleased with the progress made and remain committed to building on this momentum. We expect to enroll and dose additional patients across our clinical trial sites in Europe and advance toward the much-anticipated inflection point, which is the interim analysis,” Climaco added.

The global GBM treatment market was valued at $2.14 billion in 2020 and is expected to grow at a CAGR of 8.8% and reach an estimated value of $4.2 billion by 2028. The market’s growth is expected to be driven by the increased approval for novel therapies for GBM treatment. The special designation granted by the FDA for investigational new drugs is expected to help expedite the approval process and commercialization of these therapies (https://nnw.fm/lS9uy ).

Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical data and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This potentially pivotal study is an adaptive, multicenter, open-label, randomized, and controlled study in adult patients with recurrent GBM after the failure of standard first-line therapy. The study’s primary endpoint is Overall Survival (“OS”), an endpoint the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm.

CNS’s study will compare Berubicin to a standard of care (Lomustine), with a 2 to 1 randomization of patients to receive one of the two drugs. The recently amended protocol expands eligibility to patients who received additional treatments as a form of first-line therapy. The FDA has granted the company Fast Track Designation for Berubicin, enabling more frequent interactions with them to guide expediting the development and review process. The FDA has also granted CNS Orphan Drug Designation, which may provide seven years of marketing exclusivity upon approval of an NDA.

For more information, visit the company’s website at www.CNSPharma.com.


NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


CNS Pharmaceuticals Inc. (CNSP) Stock Research Links

CNSP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 53

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 22

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 128

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading

Top 5 Most Recently Viewed Articles

InsCorp, Inc. Experiences Significant Growth Impact in 2025

Updated Category News Views 229

InsCorp, Inc. Sees Improved Financial Metrics in 2025 InsCorp, Inc. (OTCQX: IBTN) has announced results for the second quarter of 2025, demonstrating a noticeable upward trend in earnings per share (EPS) at $0.73, an increase from $0.57 in the prior quarter and $0.63 over the same period last year. Jim Rieniets, the President and CEO of INSBANK, expressed optimism about...

Continue Reading
Revance Celebrates National Sunscreen Day with Times Square Billboard

Updated Category News Views 223

Revance Celebrates National Sunscreen Day with a Bold Message Revance is thrilled to commemorate National Sunscreen Day with a vibrant digital billboard in Times Square. This event not only marks a celebration of Blue Lizard® Australian Sunscreen but also highlights the importance of sun safety as the summer season approaches. Blue Lizard is recognized as the leading...

Continue Reading
Exploring Noah Holdings' Strategic Vision for Global Growth

Updated Category News Views 523

Noah's Global Expansion and Innovative Services Noah Holdings has actively pushed the envelope in providing innovative financial services tailored to meet the diverse wealth management requirements of its clients. This year marks a significant chapter in their journey toward international expansion, where they are introducing groundbreaking solutions along with targeted...

Continue Reading
Streamline Your Taxes: Harness QuickBooks Reports Now

Updated Category News Views 21

QuickBooks: Not Just for Bookkeeping Anymore Taxes can be a pain, but if you're rocking QuickBooks, there's a silver lining. Karen Eberhart Metcalfe, the accounting whiz from Bolingbrook, IL, assures us that this tool isn't merely for ticking boxes in bookkeeping; it's your ace for navigating tax season with less sweat and more precision. When you’ve got those reports...

Continue Reading
Vistra's Options Trading Insights: What Big Investors Indicate

Updated Category News Views 177

Understanding Vistra's Options Trading Landscape Investors are closely observing the options trading activity for Vistra (NYSE: VST) as it indicates a notable bearish sentiment among significant traders. Retail traders would benefit from being aware of these trends. Current Market Sentiment Recent data revealed on options trading history highlights that a recognizable...

Continue Reading